Moderna's COVID-19 vaccine is extremely helpful at preventing severe COVID-19 but it's hard to come by in the planet's poorer countries
- Around one million doses of
Moderna's vaccines have been sent to low-income countries.
- The company has been accused of focusing on profit, The New York Times reported.
View all Offers
- 66% OFF
Qube By Fort Collins Men's Embellished Cape Bomber Jacket (14652_Blue_Xl_Blue_XL)₹ 808₹ 2399Buy On
- 60% OFF
RIVER JJ Valaya Solid Men's Designer Denim Bandhgala Jacket_Blue_XS₹ 4499₹ 8999Buy On
- 52% OFF
Allen Solly Junior Boy's Girl's Jacket (ABJKEGLPT94157_Yellow_13 Years-14 Years)₹ 1799₹ 1799Buy On
- 80% OFF
RIVER Men's Blazer ASHISH N Soni Notch Lapel Regular fit with Full Sleeve (Blue Night, S)₹ 7989₹ 8999Buy On
- 80% OFF
Cloth Theory Boy's CTKDWINCN013_Grey_11-12 Years Cotton Sweatshirt Grey2₹ 1099₹ 1099Buy On
Poorer countries have received significantly fewer doses of Moderna's vaccine compared to wealthier nations, The New York Times reported.
Data from Airfinity, a firm that tracks vaccine shipments, showed only about a million of Moderna's vaccine doses have gone to low-income countries compared to 8.4 million doses of Pfizer's vaccine and around 25 million of Johnson & Johnson's vaccine.
The Times also reported that a few middle-income countries have had to pay more for the vaccine than the United States, while others like Botswana have made deals with Moderna but have yet to receive their doses, and others like Tunisia haven't even been able to get in touch with Moderna.
Moderna's vaccine appears to offer better protection compared to Pfizer's and Johnson & Johnson's over time, Insider previously reported. Data collected from hospitals in 20 cities showed that after four months, Moderna's vaccine was 92% effective at preventing hospitalizations. During the same period, Pfizer's effectiveness had dropped to 77% and Johnson & Johnson's to 68%.
In a press release, the company said: "From the beginning, our goal has been to help protect as many people as possible around the globe. To date, more than 250 million people have been vaccinated globally with the Moderna COVID-19 vaccine. However, we recognize that access to vaccines continues to be a challenge in many parts of the world. So, we remain focused on implementing a comprehensive and always evolving strategy to ensure that low-income countries get access to our vaccine."
According to Times, executives said they're making as many doses as possible but their "production capacity is limited" and doses produced are going towards existing orders.
Dr. Tom Frieden, a former head of the Centers for Disease Control and Prevention told The Times the company is "behaving as if they have absolutely no responsibility beyond maximizing the return on investment."
In their press release, Moderna said there were five "pillars" to expanding vaccine access:
- Not enforcing the patent on their vaccine
- A May 2021 agreement with COVAX to provide 500 million doses
- Working with governments who plan to donate vaccines to COVAX
- building a state-of-the-art mRNA facility in Africa, but did not specify when
- Investing to expand capacity to deliver an additional billion vaccines to low-income countries next year.
There's been a disparity overall in vaccination rates between wealthy countries and low-income countries. While more than 46% of the world's population has received at least one dose of a COVID-19 vaccine, that number is not evenly distributed, with only 2.5% of people in low-income countries getting at least one dose.
Countries like the United Arab Emirates, Portugal, and Singapore lead the way with more than 80% of their populations fully vaccinated. Less than 1% of the population in countries like South Sudan, Uganda, and Ethiopia are fully vaccinated.
Moderna did not respond to Insider's email request for comment at the time of publication.
- Amazon Great Republic Sale: Top deals on recliners, sofas and more home furnishing items
- Best fashion and beauty deals during Amazon sale
- Amazon Great Republic Day Sale — Best audio deals on headphones, speakers
- GST on salaries? A new ruling can cause a lot of confusion and litigation
- Nykaa's rival Purplle raises $38 million from Pantaloon’s CEO, Sequoia